Cas:67738-67-4 [3aα,4α(E),5β,6aα]-(+/-)-4-[4-(3-chlorophenoxy)-3-oxo-1-butenyl]-hexahydro-5-hydroxy-2H-cyclopenta[b]-furan-2-one manufacturer & supplier

Chemical Name:[3aα,4α(E),5β,6aα]-(+/-)-4-[4-(3-chlorophenoxy)-3-oxo-1-butenyl]-hexahydro-5-hydroxy-2H-cyclopenta[b]-furan-2-one

CAS.NO:67738-67-4

Synonyms:7α-hydroxy-6β-(3-oxo-4-m-chlorophenoxy-1E-butenyl)-2-oxabicyclo[3.3.0]octan-3-one;4-[(1E)-4-(3-Chlorophenoxy)-3-oxo-1-buten-1-yl]-5-hydroxyhexahydro-2H-cyclopenta[b]furan-2-one;2H-Cyclopenta[b]furan-2-one, 4-[(1E)-4-(3-chlorophenoxy)-3-oxo-1-buten-1-yl]hexahydro-5-hydroxy-;γ-lactone of 2β-(4-m-chlorophenoxy-3-oxo-trans-1-butenyl)-3α,5α-dihydroxycyclopentyl-1α-acetic acid

Molecular Formula:C₁₇H₁₇ClO₅

Molecular Weight:336.767

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:537.8±50.0 °C at 760 mmHg

Density:1.4±0.1 g/cm3

Index of Refraction:1.637

PSA:72.83000

Exact Mass:336.076447

LogP:0.65

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 7α-hydroxy-6β-(3-oxo-4-m-chlorophenoxy-1E-butenyl)-2-oxabicyclo[3.3.0]octan-3-one chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,γ-lactone of 2β-(4-m-chlorophenoxy-3-oxo-trans-1-butenyl)-3α,5α-dihydroxycyclopentyl-1α-acetic acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,4-[(1E)-4-(3-Chlorophenoxy)-3-oxo-1-buten-1-yl]-5-hydroxyhexahydro-2H-cyclopenta[b]furan-2-one Use and application,2H-Cyclopenta[b]furan-2-one, 4-[(1E)-4-(3-chlorophenoxy)-3-oxo-1-buten-1-yl]hexahydro-5-hydroxy- technical grade,usp/ep/jp grade.

Related News: RELATED: CVS, Walgreens begin rolling out over-the-counter COVID tests from Abbott, Ellume and more [3aα,4α(E),5β,6aα]-(+/-)-4-[4-(3-chlorophenoxy)-3-oxo-1-butenyl]-hexahydro-5-hydroxy-2H-cyclopenta[b]-furan-2-one manufacturer AXON is planning a follow-up trial that will include a better-defined group of Alzheimer’s patients suffering from both amyloid plaques and tau tangles, Novak said. [3aα,4α(E),5β,6aα]-(+/-)-4-[4-(3-chlorophenoxy)-3-oxo-1-butenyl]-hexahydro-5-hydroxy-2H-cyclopenta[b]-furan-2-one supplier Novavax, a Maryland biotechnology company that has struggled mightily with delays in developing its coronavirus vaccine, announced Monday that its two-shot regimen was over 90% effective overall in a trial that unfolded even as more contagious variants emerged. [3aα,4α(E),5β,6aα]-(+/-)-4-[4-(3-chlorophenoxy)-3-oxo-1-butenyl]-hexahydro-5-hydroxy-2H-cyclopenta[b]-furan-2-one vendor Compared with existing Imbruvica therapies, where patients take the BTK inhibitor daily—potentially for years—until their disease progresses, the new Venclexta combo caps treatment at about 14 months. That could offer a new option for “probably younger patients with CLL that prefer more flexible, treatment-free intervals,” said Craig Tendler, M.D., vice president of oncology clinical development and global medical affairs at J&J’s Janssen unit, during an interview. [3aα,4α(E),5β,6aα]-(+/-)-4-[4-(3-chlorophenoxy)-3-oxo-1-butenyl]-hexahydro-5-hydroxy-2H-cyclopenta[b]-furan-2-one factory RELATED: CVS, Walgreens begin rolling out over-the-counter COVID tests from Abbott, Ellume and more